ENTITY
SciClone Pharmaceuticals

SciClone Pharmaceuticals (SCICLONE HK)

108
Analysis
Health Care • China
SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.
more
bullish•Alibaba Health
•18 Dec 2020 20:56

China Healthcare: Macro Themes

This Insight summarizes the takeaways from a recent China healthcare industry conference.  There is much talk of pressures on the industry, but...

Share
•06 Oct 2020 14:29

SciClone Pharma (赛生药业) Pre-IPO: Rejuvenation of Old Drugs

SciClone Pharma was founded in the US but has a focus on sales of oncology and infectious disease drugs in China. The company plans to raise up to...

Logo
752 Views
Share
x